
Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.
Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock’s crash Sunday night.